Research programme: fibroblast growth factors - Metacrine/Novo Nordisk

Drug Profile

Research programme: fibroblast growth factors - Metacrine/Novo Nordisk

Alternative Names: FGF-1 variants - Metacrine/Novo Nordisk

Latest Information Update: 21 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Metacrine
  • Developer Metacrine; Novo Nordisk
  • Class Antihyperglycaemics; Fibroblast growth factors; Proteins
  • Mechanism of Action Fibroblast growth factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Diabetes mellitus

Most Recent Events

  • 17 Aug 2017 Metacrine receives patent allowance for FGF1 protein in USA
  • 15 Aug 2017 Metacrine and Novo Nordisk agree to collaborate for fibroblast growth factors in USA for Diabetes mellitus
  • 15 Aug 2017 Early research in Diabetes mellitus in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top